Skip to main content
S&P 5007,711.39+1.88%DOW53,299.40+2.92%NASDAQ25,908.97+2.12%BTC$80,583.00+3.78%ETH$2,432.70+5.90%GOLD$4,078.50+3.50%OIL$88.26-8.15%
Smart Investors Daily
SID Premium
NC

NASDAQ · NCNA

NuCana plc

Healthcare · Biotechnology

$1.00

Up+$0.01 (+1.00%)

Updated Nov 4, 2026, 6:18 PM

SID Score

3.0/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
24.41M
P/E ratio
-0.1
Dividend yield
0.00%
52-week range
$0.95 – $2.39
Volume
14.62K
Avg. volume
362.72K

Price performance · NCNA

NCNA price history

1M range · 0 trading sessions · Daily adjusted prices

NCNA does not have enough price history for the selected period.

Data unavailable

Market data is busy. Please try again shortly.

Latest NCNA news

The latest Smart Investors Daily articles mentioning NCNA.

Stock researchCompany · Overview

NCNA research

Overview

Company profile and research snapshot.

Company profile

NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
NCNA recent ratings
DateFirmRatingTarget
Sep 3, 2024OppenheimerOutperform—
Aug 30, 2024William BlairMarket Perform—
Aug 19, 2024OppenheimerOutperform—
Jul 23, 2024OppenheimerOutperform—
Jul 22, 2024OppenheimerOutperform—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 30, 2026

NuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in Europe

NUC-7738 is protected by over 85 issued patents worldwideEDINBURGH, United Kingdom, Sept. 30, 2026 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) (“NuCana” or the “Company”) announced that the European Patent Office (“EPO”) has granted an important patent covering the composition of matter for NUC-7738. This patent (EP 3683225) is a key component of the patent protection for NUC-7738, which currently consists of over 85 issued patents worldwide. The composition-of-matter patent covers the chemica

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By